HMDB0001377 | Oxygen | 7782-44-7 | | O2 | 31.9988 31.989829244 | Not Available |
HMDB0000051 | Ammonia | 7664-41-7 | | H3N | 17.0305 17.026549101 | Not Available |
HMDB0003125 | Hydrogen peroxide | 7722-84-1 | | H2O2 | 34.0147 34.005479308 | Not Available |
HMDB0002111 | Water | 7732-18-5 | | H2O | 18.0153 18.010564686 | Not Available |
HMDB0000164 | Methylamine | 74-89-5 | | CH5N | 31.0571 31.042199165 | Not Available |
HMDB0004077 | 4,6-Dihydroxyquinoline | 3517-61-1 | | C9H7NO2 | 161.1574 161.047678473 | Not Available |
HMDB0060289 | Quinoline-4,8-diol | | | C9H7NO2 | 161.1574 161.047678473 | Not Available |
HMDB0000068 | Epinephrine | 51-43-4 | | C9H13NO3 | 183.2044 183.089543287 | Not Available |
HMDB0000819 | Normetanephrine | 97-31-4 | | C9H13NO3 | 183.2044 183.089543287 | Not Available |
HMDB0000022 | 3-Methoxytyramine | 554-52-9 | | C9H13NO2 | 167.205 167.094628665 | Not Available |
HMDB0002182 | Phenylephrine | 59-42-7 | | C9H13NO2 | 167.205 167.094628665 | Not Available |
HMDB0001942 | Phenylpropanolamine | 14838-15-4 | | C9H13NO | 151.2056 151.099714043 | Not Available |
HMDB0004076 | 5-Hydroxykynurenamine | 708-23-6 | | C9H12N2O2 | 180.2038 180.089877638 | Not Available |
HMDB0060281 | 3-Hydroxykynurenamine | | | C9H12N2O2 | 180.2038 180.089877638 | Not Available |
HMDB0014890 | Tranylcypromine | 155-09-9 | | C9H11N | 133.1903 133.089149357 | - Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
- Salsali M, Holt A, Baker GB: Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol. 2004 Feb;24(1):63-76. [PubMed:15049511 ]
- Volz HP, Gleiter CH: Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging. 1998 Nov;13(5):341-55. [PubMed:9829163 ]
- Shioda K, Nisijima K, Yoshino T, Kato S: Mirtazapine abolishes hyperthermia in an animal model of serotonin syndrome. Neurosci Lett. 2010 Oct 4;482(3):216-9. doi: 10.1016/j.neulet.2010.07.039. Epub 2010 Jul 23. [PubMed:20655983 ]
- Gatch MB, Taylor CM, Flores E, Selvig M, Forster MJ: Effects of monoamine oxidase inhibitors on cocaine discrimination in rats. Behav Pharmacol. 2006 Mar;17(2):151-9. [PubMed:16495723 ]
- Lang W, Masucci JA, Caldwell GW, Hageman W, Hall J, Jones WJ, Rafferty BM: Liquid chromatographic and tandem mass spectrometric assay for evaluation of in vivo inhibition of rat brain monoamine oxidases (MAO) A and B following a single dose of MAO inhibitors: application of biomarkers in drug discovery. Anal Biochem. 2004 Oct 1;333(1):79-87. [PubMed:15351283 ]
- Shioda K, Nisijima K, Yoshino T, Kato S: Extracellular serotonin, dopamine and glutamate levels are elevated in the hypothalamus in a serotonin syndrome animal model induced by tranylcypromine and fluoxetine. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jul;28(4):633-40. [PubMed:15276688 ]
- Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression]. Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3. [PubMed:14574774 ]
- Cohen C, Curet O, Perrault G, Sanger DJ: Reduction of oral ethanol self-administration in rats by monoamine oxidase inhibitors. Pharmacol Biochem Behav. 1999 Nov;64(3):535-9. [PubMed:10548268 ]
- Wiest SA, Steinberg MI: 3H[2-(2-benzofuranyl)-2-imidazoline] (BFI) binding in human platelets: modulation by tranylcypromine. Naunyn Schmiedebergs Arch Pharmacol. 1999 Aug;360(2):209-16. [PubMed:10494892 ]
- Loscher W, Lehmann H, Teschendorf HJ, Traut M, Gross G: Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy. J Pharmacol Exp Ther. 1999 Mar;288(3):984-92. [PubMed:10027835 ]
- Todd KG, Baker GB: GABA-elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (-)-deprenyl and clorgyline. J Affect Disord. 1995 Dec 13;35(3):125-9. [PubMed:8749840 ]
- Finberg JP, Youdim MB: Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology. 2002 Dec;43(7):1110-8. [PubMed:12504917 ]
|
HMDB0004061 | 3-Methoxy-4-hydroxyphenylglycolaldehyde | 17592-23-3 | | C9H10O4 | 182.1733 182.057908808 | Not Available |
HMDB0005175 | Homovanillin | 5703-24-2 | | C9H10O3 | 166.1739 166.062994186 | Not Available |
HMDB0006242 | 3,4-Dihydroxymandelaldehyde | 13023-73-9 | | C8H8O4 | 168.1467 168.042258744 | Not Available |
HMDB0003791 | 3,4-Dihydroxyphenylacetaldehyde | 5707-55-1 | | C8H8O3 | 152.1473 152.047344122 | Not Available |
HMDB0003767 | 4-Hydroxyphenylacetaldehyde | 7339-87-9 | | C8H8O2 | 136.1479 136.0524295 | Not Available |
HMDB0006236 | Phenylacetaldehyde | 122-78-1 | | C8H8O | 120.1485 120.057514878 | Not Available |
HMDB0015045 | Zonisamide | 68291-97-4 | | C8H8N2O3S | 212.226 212.025562822 | - Murata M: Zonisamide: a new drug for Parkinson's disease. Drugs Today (Barc). 2010 Apr;46(4):251-8. doi: 10.1358/dot.2010.46.4.1490077. [PubMed:20502722 ]
- Okada M, Kaneko S, Hirano T, Mizuno K, Kondo T, Otani K, Fukushima Y: Effects of zonisamide on dopaminergic system. Epilepsy Res. 1995 Nov;22(3):193-205. [PubMed:8991786 ]
|
HMDB0014752 | Furazolidone | 67-45-8 | | C8H7N3O5 | 225.16 225.038570337 | - Timperio AM, Kuiper HA, Zolla L: Identification of a furazolidone metabolite responsible for the inhibition of amino oxidases. Xenobiotica. 2003 Feb;33(2):153-67. [PubMed:12623758 ]
- Ali BH: Pharmacological, therapeutic and toxicological properties of furazolidone: some recent research. Vet Res Commun. 1999 Oct;23(6):343-60. [PubMed:10543364 ]
- Hoogenboom LA, Tomassini O, Oorsprong MB, Kuiper HA: Use of pig hepatocytes to study the inhibition of monoamine oxidase by furazolidone. Food Chem Toxicol. 1991 Mar;29(3):185-91. [PubMed:2032659 ]
|
HMDB0014918 | Phenelzine | 51-71-8 | | C8H12N2 | 136.1943 136.100048394 | - Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
- Volz HP, Gleiter CH: Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging. 1998 Nov;13(5):341-55. [PubMed:9829163 ]
- Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression]. Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3. [PubMed:14574774 ]
- Chiche F, Le Guillou M, Chetrite G, Lasnier F, Dugail I, Carpene C, Moldes M, Feve B: Antidepressant phenelzine alters differentiation of cultured human and mouse preadipocytes. Mol Pharmacol. 2009 May;75(5):1052-61. doi: 10.1124/mol.108.052563. Epub 2009 Feb 6. [PubMed:19201819 ]
- Chenu F, El Mansari M, Blier P: Long-term administration of monoamine oxidase inhibitors alters the firing rate and pattern of dopamine neurons in the ventral tegmental area. Int J Neuropsychopharmacol. 2009 May;12(4):475-85. doi: 10.1017/S1461145708009218. Epub 2008 Aug 13. [PubMed:18700056 ]
- Wooters TE, Bardo MT: The monoamine oxidase inhibitor phenelzine enhances the discriminative stimulus effect of nicotine in rats. Behav Pharmacol. 2007 Nov;18(7):601-8. [PubMed:17912044 ]
- Pickar D, Murphy DL, Cohen RM, Campbell IC, Lipper S: Selective and nonselective monoamine oxidase inhibitors: behavioral disturbances during their administration to depressed patients. Arch Gen Psychiatry. 1982 May;39(5):535-40. [PubMed:7092487 ]
- MacKenzie EM, Grant SL, Baker GB, Wood PL: Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition. Neurochem Res. 2008 Mar;33(3):430-6. Epub 2007 Aug 31. [PubMed:17768678 ]
- McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH: The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf. 2006 Jan;5(1):157-68. [PubMed:16370964 ]
|
HMDB0000216 | Norepinephrine | 51-41-2 | | C8H11NO3 | 169.1778 169.073893223 | Not Available |